Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 3, 2015, Pages 291-301

  Fedele, Palma ^a   Orlando, Laura ^a   Schiavone, Paola ^a   Calvani, Nicola ^a   Caliolo, Chiara ^a   Quaranta, Annamaria ^a   Nacci, Angelo ^a   Cinieri, Saverio ^a,b  

^a A Perrino Hospital   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Endocrine resistance; Endocrine therapy; Metastatic breast cancer; Next generation sequencing technologies; Targeted agents

Indexed keywords

ABEMACICLIB; ALPELISIB; ANASTROZOLE; AXITINIB; AZD 8931; BEVACIZUMAB; CEDIRANIB; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; PALBOCICLIB; PAZOPANIB; RIBOCICLIB; SOMATOMEDIN C; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RAPAMYCIN;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMENOPAUSE; PREMENOPAUSE; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATITIS; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIROLIMUS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84928824091     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.01.001     Document Type: Review

References (69)

1. Bartlett J.M., Brookes C.L., Robson T., et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2011, 29(12):1531-1538.
2. Arpino G., Weichmann L., Osborne C.K., et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family. Endocr Rev 2008, 29:217-233.
3. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247.
4. Hayes E., Nicholson R.I., Hiscox S. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci 2011, 16:838-848.
5. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643.
6. Fedele P., Calvani N., Marino A., et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?. Crit Rev Oncol Hematol 2012, 84(2):243-251.
7. Vasan N., Yelensky R., Wang K., et al. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist 2014, 19(5):453-458.
8. Finn R.S., Crown J.P., Lang I., et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18). American Association for Cancer Research Annual Meeting 2014 2014, [Abstr CT101].
9. Yardley D.A., Ismail-Khan R.R., Melichar B., et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013, 10:2128-2135.
10. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010, 7:209-219.
11. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637.
12. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30:2718-2724.
13. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
14. Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21(3):242-252.
15. Cardoso F., Senkus-Konefka E., Fallowfield L., et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2010, 21(5):vii15-vii19.
16. Riemsma R1, Forbes C.A., Kessels A., et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 2010, 123(1):9-24.
17. Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26(30):4883-4890.
18. Howell A., Robertson J.F., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22(9):1605-1613.
19. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000, 18(7):1399-1411.
20. Osborne CK1, Pippen J., Jones S.E. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20(16):3386-3395.
21. Cristofanilli M., Valero V., Mangalik A., et al. Phase II, randomized trial 653 to compare anastrozole combined with gefitinib or placebo in post-menopausal women with hormone receptor-positive metastatic breast cancer. J Clin Cancer Res 2010, 16(6):1904-1914.
22. Osborne C.K., Neven P., Dirix L.Y., et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17:1147-1159.
23. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for post-menopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33):5538-5546.
24. Wolff A.C., Lazar A.A., Bondarenko I., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013, 10:195-202.
25. Bergh J., Jönsson P.E., Lidbrink E.K., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012, 30(16):1919-1925.
26. Johnston S.R., Kilburn L.S., Ellis P., et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013, 14:989-998.
27. Mehta R.S., Barlow W.E., Albain K.S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367:435-444.
28. Aesoy R., Sanchez B.C., Norum J.H., et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008, 6:1630-1638.
29. Yardley D.A., Burris H.A., Clark B.L. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor positive metastatic breast cancer; a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer 2011, 11:146-152.
30. Forero-Torres A., Saleh M.N., Galleshaw J.A., et al. Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor or progesterone receptor positive breast cancer. Clin Breast Cancer 2010, 10(4):275-280.
31. Martin M., Loibi S., von Minckwitz G., et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - first efficacy results from the LEA study. Cancer Res 2012, 72(Suppl. 24). [Abstract nr S1-7].
32. Loibi S., De la Haba J., von Minckwitz G., et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer. Final analysis of the LEA study. 2013 European Cancer Congress 2013, [Abstract 1851].
33. Giovannini M., Aldrighetti D., Zucchinelli P., et al. Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol 2010, 76:13-35.
34. Hyams D.M., Chan A., De Oliveira C., et al. Cediranib in combination with fulvestrant in hormone sensitive metastatic breast cancer; a randomized phase II study. Invest New Drugs 2013, 31:1345-1354.
35. Hickinson D.M., Klinowska T., Speake G., et al. AZD8931, an equipotent, reversible, inhibitor of signaling by epidermal growth factor receptor, ERBB2 (Her2), and ERBB3; an unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 2010, 16(4):15.
36. Johnston S., Basik M., Hegg R., Lausoontornsiri W., et al. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J Clin Oncol 2013, 31. [suppl. abstr 531].
37. Finn R.S., Dering J., Conklin D. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009, 11(5):R77.
38. Patnaik A., Rosen L.S., Tolaney S.M., et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. Proceedings American Association for Cancer Research Annual Meeting 2014 2014, [Abstract CT232].
39. -- reactivating Rb in cancer. 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013 2013, [Abstract B264].
40. Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer. (MONALEESA-2). Available from: . https://clinicaltrials%20gov/.
41. Slamon D.J., Hurvitz S.A., Applebaum S., et al. Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. J Clin Oncol 2010, 28(15s). [suppl; abstr 3060].
42. A study of palbociclib (PD-0332991)+letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer (PALOMA-2), . https://clinicaltrials.gov/.
43. A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). Available from: . https://clinicaltrials.gov/.
44. Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer. Available from: . https://clinicaltrials.gov/.
45. Jang E.R., Lim S.J., Lee E.S., et al. The histone deacetylase inhibitor trichostatin sensitizes estrogen receptor α- negative breast cancer cells to tamoxifen. Oncogene 2004, 23(9):1724-1730.
46. Duong V., Licznar A., Margueron R., et al. ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2006, 25(12):1799-1806.
47. Exemestane with or without entinostat in treating postmenopausal patients with recurrent hormone receptor positive breast cancer that is locally advanced or metastatic. Available from: . https://clinicaltrials.gov/.
48. Schmelzle T., Hall M. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
49. Di Cosimo S., Scaltriti M., Val D., et al. The PI3K/AKT/mTOR pathway as a target for breast cancer therapy. J Clin Oncol 2007, 25(Suppl. 18):3511.
50. Dobashi Y., Watanabe Y., Miwa C., et al. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011, 4(5):476-495.
51. De Graffenried L.A., Friedrichs W.E., Russell D.H., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004, 10(23):8059-8067.
52. Massarweh S., Romond E., Black E.P., et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat 2014, 143(2):325-332.
53. Baselga J., Campone M., Sahmoud T., et al. Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 phase III trial. European Multidisciplinary Cancer Congress (EMCC) 2011 2011, [Abstract 9LBA].
54. Hortobagy G.N., PiccartM, Rugo H., et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 Phase III Trial. Cancer Res. 2011, 71(Suppl. 24):S3-S7. [abstract no. S3-7].
55. Yardley D.A., Noguchi S., Pritchard K.I., et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013, 30:870-884.
56. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670.
57. Burris H., Gnant M., Hortobagyi G., et al. Characterization of response to everolimus (EVE) in BOLERO-2: a phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer. SABCS 2013 2013, P2-16-17.
58. Campone M., Bachelot T., Gnant M., et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer 2013, 49:2621-2632.
59. Rugo H., Campone M., Gnant M., et al. BOLERO-2: efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer. J Clin Oncol 2013, 31. [Abstract 152].
60. Burris H.A., Lebrun F., Rugo H.S., et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013, 119:1908-1915.
61. Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+, HER2- metastatic or locally advanced breast cancer (Bolero-4), . Available from: . https://clinicaltrials%20gov/.
62. Hormone therapy with or without everolimus in treating patients with breast cancer, US. Available from: . https://clinicaltrials%20gov/.
63. Safety study of mTOR inhibitors everolimus to adjuvant hormone therapy in women with poor prognosis, ER-positive and HER2-negative primary breast cancer, free of disease after receiving 3 years of adjuvant hormone therapy, . Available from: . https://clinicaltrials%20gov/.
64. A Phase II study of eveIrolimus in combination with exemestane versus everolimus alone versus capecitabine in advanced breast cancer. Available from: . https://clinicaltrials%20gov/.
65. Study of Fulvestrant±everolimus in postmenopausal, hormone receptor positive metastatic breast cancer resistant to aromatase inhibitors. Available from: . https://clinicaltrials%20gov/.
66. Phase III study of BKM120/placebo with fulvestrant in postmenopausal patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer refractory to aromatase inhibitor. BELLE2. Available from: . https://clinicaltrials%20gov/.
67. A study of Ridaforolimus (MK-8669) in combination with Dalotuzumab (MK-0646) compared to standard of care treatment in estrogen receptor positive breast cancer patients. Available from: . https://clinicaltrials%20gov/.
68. Treilleux I., Arnedos M., Cropet C., et al. Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD trial translational study. J Clin Oncol 2013, 31. [Abstract 510].
69. Hortobagyi G., Piccart-Gebhart M., Rugo H., et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 2013, 31. [Abstract LBA509].